Teemu Murtola

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Prostatectomy 35%
3. Hydroxymethylglutaryl-CoA Reductase Inhibitors 30%
4. Prostate 17%
5. Hypoglycemic Agents 17%
6. Androgens 16%
7. Cohort Studies 15%
8. Finland 14%
9. Atorvastatin 13%
10. Early Detection of Cancer 12%
11. Prostate-Specific Antigen 12%
12. Survival 11%
13. Pharmaceutical Preparations 11%
14. Population 11%
15. Neoplasms 10%
16. Cholesterol 10%
17. Mortality 9%
18. Metformin 9%
19. Anti-Inflammatory Agents 9%
20. Drug Users 8%
21. Erectile Dysfunction 8%
22. Antihypertensive Agents 8%
23. Incidence 7%
24. Recurrence 7%
25. Randomized Controlled Trials 7%
26. menthyl 3-(2-pyridylsulfinyl)acrylate 7%
27. Adaptive Clinical Trials 7%
28. Phenomics 6%
29. Registries 6%
30. MicroRNAs 6%
31. alfuzosin 6%
32. Case-Control Studies 6%
33. Simvastatin 6%
34. 5-alpha Reductase Inhibitors 6%
35. oxidized low density lipoprotein 6%
36. Aspirin 5%
37. Tamsulosin 5%
38. Epithelial Cells 5%
39. Serum 5%
40. Transposases 5%
41. Prescriptions 5%
42. Sotalol 5%
43. LDL Cholesterol 5%
44. Breast Neoplasms 5%
45. Therapeutics 5%
46. Allopurinol 5%